Philips shares surge on US recall settlement news
To pay $1.1 bln to settle U.S. claims
Settlement smaller than expected -analysts
Ends U.S. litigation over recalled devices
Shares surge 35%
Adds statement from plaintiffs' attorneys in paragraphs 16-17
By Bart H. Meijer
AMSTERDAM, April 29 (Reuters) -Philips PHG.AS shares surged 35% early on Monday as the medical devices maker announced a smaller-than-expected settlement to resolve claims over recalled breathing devices in the United States.
Philips said it had agreed to pay $1.1 billion to settle all personal injury claims filed in the U.S., ending uncertainty that had slashed its market value over the past three years.
"This settlement is significantly lower than expectations of $2-4 billion and worst case of $10 billion," Barclays analysts said.
"It comes a lot earlier than anticipated and removes an overhang many have worried would linger for years."
Amsterdam-based Philips has grappled with the fallout of its recall of millions of breathing devices and ventilators for three years, as fears of large litigation bills lopped off about two-thirds of its market value.
Its shares were up 35% at 26.60 euros at 0810 GMT, hitting their highest level since April 2022 though still only worth half as much as before the recall started in June 2021.
The devices were recalled because of concerns that foam used in them could degrade and become toxic, carrying potential cancer risks.
CEO Roy Jakobs declined to say whether the bill was smaller than he had feared.
"$1.1 billion is a significant amount, however you put it. This is important to end uncertainty and to provide clarity on our way forward," he told reporters.
Philips is still facing lawsuits in Europe over the devices, but Jakobs said this settlement would end most of the uncertainty for investors.
"Totalling the total U.S. cases that we have now finalised, so economic loss, medical monitoring and personal injury, then the vast majority of claims is actually put to bed."
The company said it did not admit any fault or liability, or that any injuries were caused by its devices.
Philips this month announced the final details of a consent decree reached with U.S. authorities in January, spelling out the improvements it needs to make at its Respironics plants in the United States.
It said it had now also reached agreement with insurers over compensation of 540 million euros ($580 million) for product liability costs, to be received in the second quarter of 2024.
It booked a provision of 982 million euros in its first-quarter results for the settlement payments, which it expects to fund from cash flow next year.
Lawyers for plaintiffs in the lawsuits said in a joint statement Monday that they were pleased with the outcome.
"Ultimately, these combined agreements accomplish what we sought to achieve when this litigation began - holding Philips accountable by obtaining care for those with physical injuries and compensation for those needing new respiratory devices," they said.
ORDERS AND RESULTS
Philips on Monday also reported its first-quarter earnings, which beat analyst expectations with an 8% jump in adjusted earnings before interest, taxes and amortisation (EBITA) to 388 million euros.
That beat the 361 million euros, roughly stable from a year before, expected by analysts in a company-compiled poll.
Comparable sales growth of 2.4% was in line with expectations, leading to a higher-than-expected 9.4% profit margin.
Order intake, however, continued to fall due to slower sales in China and was 3.8% lower than in the first three months of 2023.
"We started the year in line with our plan," Jakobs said. "With order intake growth outside China turning positive and strong margin improvement."
Reporting by Bart Meijer; editing by Subhranshu Sahu, Louise Heavens, Jason Neely and Jonathan Oatis
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
